Patents by Inventor James Brian Parent

James Brian Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20240092938
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: February 13, 2023
    Publication date: March 21, 2024
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20230391889
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 10, 2023
    Publication date: December 7, 2023
    Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 11613589
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 28, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20210054099
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: April 24, 2020
    Publication date: February 25, 2021
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20200190215
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 13, 2019
    Publication date: June 18, 2020
    Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 10683367
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 16, 2020
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20200040104
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 8, 2019
    Publication date: February 6, 2020
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Clark E. Tedford, James Brian Parent
  • Compositions for Inhibiting MASP-2 Dependent Complement Activation
    Publication number: 20190119402
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: July 13, 2018
    Publication date: April 25, 2019
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation
    Publication number: 20180291112
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 11, 2018
    Publication date: October 11, 2018
    Inventors: Hans-Wilhelm Schwaeble, Thomas Dudler, Clark E. Tedford, James Brian Parent, Gregory A. Demopulos
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20180291111
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 11, 2018
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Clark E. Tedford, James Brian Parent
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 10047165
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20170233493
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 25, 2016
    Publication date: August 17, 2017
    Inventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James Brian Parent, Teizo Fujita
  • Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation
    Publication number: 20170233494
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 12, 2016
    Publication date: August 17, 2017
    Inventors: Hans-Wilhelm Schwaeble, Thomas Dudler, Clark E. Tedford, James Brian Parent, Gregory A. Demopulos
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20170166660
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 27, 2016
    Publication date: June 15, 2017
    Inventors: Hans-Wilhelm Schwaeble, Clark E. Tedford, James Brian Parent
  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20170088632
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: September 13, 2016
    Publication date: March 30, 2017
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 9475885
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: October 25, 2016
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    Publication number: 20160272727
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 7, 2016
    Publication date: September 22, 2016
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Clark E. Tedford, James Brian Parent
  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20160002349
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: March 17, 2015
    Publication date: January 7, 2016
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 9011860
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: April 21, 2015
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation
    Publication number: 20140205598
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 30, 2014
    Publication date: July 24, 2014
    Applicants: University of Leicester, Omeros Corporation
    Inventors: Hans-Wilhelm Schwaeble, Thomas Dudler, Clark E. Tedford, James Brian Parent, Gregory A. Demopulos